Beransa (Bedinvetmab) 30mg Injection (2 Vials)

PRESCRIPTION REQUIRED FOR THIS ITEM

This item is a prescription medication. A prescription is required from your veterinarian before we can supply this product. Please ensure that you have read the "How to Order" page before ordering this item.

All of Pet Care Pharmacy’s prescription medications are APVMA or TGA approved and are also identical to those supplied by your veterinarian.

Description

• Beransa (bedinvetmab) is indicated for the alleviation of pain associated with osteoarthritis in dogs.
• Beransa is a canine therapeutic monoclonal antibody (mAb) that neutralises Nerve Growth Factor (NGF).
• The inhibition of NGF-mediated cell signalling has been demonstrated to provide relief from pain associated with osteoarthritis.

Recommendations for use

Beransa alleviates pain associated with osteoarthritis

• A once-a-month subcutaneous injection
• Provides long- acting and well-tolerated pain relief for dogs with OA pain
• Works differently to NSAIDs by specifically targeting Nerve Growth Factor (NGF) a key player in osteoarthritis (OA) pain
• Beransa is eliminated via normal protein degradation pathways —just like naturally produced antibodies — with minimal impact on the liver, kidneys and GIT
• No known interactions with other medicinal product such as vaccines, parasiticides, nutritional supplements or antimicrobials
• Administration must be conducted under the supervision of a veterinarian

Dosage

• The recommended dosage is 0.5-1.0 mg/kg bodyweight, administered subcutaneously, once a month
• Each vial delivers 1 mL volume for injection. For dogs weighing <5.0 kg: aseptically withdraw 0.1 mL/kg from a single 5 mg/mL vial and administer subcutaneously. For volumes ≤0.5 mL, use an adequate syringe size and dose to the nearest 0.1 mL.
• For dogs above 60 kg, the contents of more than one vial are required to administer a single dose. In those cases, withdraw the content from each required vial into the same syringe and administer as a single subcutaneous injection (2 mL).
• Dose according to the dosing chart below:

  Storage

• Store between 2 °C and 8 °C (refrigerate, do not freeze)
• Store in the original package
• Protect from light
• Avoid excessive shaking
• Once opened, contents of the vial should be used immediately and any remaining solution should be disposed

Additional user safety

• Take care to avoid self-injection. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or label to the Medical Practitioner.
• For pregnant women, women trying to conceive, and breastfeeding women, the importance of Nerve Growth Factor (NGF) in ensuring normal foetal nervous system development is well established and laboratory studies conducted on non-human primates with human anti-NGF antibodies have shown evidence of reproductive and developmental toxicity.
• Pregnant women, women trying to conceive, and breastfeeding women should take extreme care to avoid accidental self-injection or needle stick injuries.
• Consult a Medical Practitioner if such an injection occurs.
• Hypersensitivity reactions, including anaphylaxis, could potentially occur in the case of accidental self-injection. Repeated self-administration may increase the risk of hypersensitivity reactions.
• Wash hands after use.

First Aid Statement

• If poisoning occurs, contact a doctor or Poisons Information Centre. Phone Australia 131126.

Contraindications

• This product must not be used in dogs intended for breeding.
• This product must not be used in pregnant or lactating dogs as Nerve Growth Factor (NGF) plays a key role in foetal nervous system development.
• This product must not be used in dogs under 12 months of age.
• This product must not be used in dogs with hypersensitivity to bedinvetmab.

Side Effects

• Mild reactions at the injection site (e.g. swelling and heat) may uncommonly be observed.
• Hypersensitivity-type reactions have been reported very rarely. In case of such reactions, appropriate symptomatic treatment should be administered.

Precautions

• This product may induce transient or persistent anti-drug antibodies. The induction of such antibodies is uncommon and may have no effect, or may result in a decrease in efficacy in animals that responded to treatment previously. If no or limited response is observed within one month after initial dosing, an improvement in response may be observed after administration of a second dose one month later. However, if the animal does not show a better response after the second dose, the veterinarian should consider alternative treatments.

10023666